MTCR News and Press, Metacrine Inc. From 12/27/21

Metacrine (NASDAQ:MTCR) has announced the resignation of Chief Medical Officer (CMO) Hubert Chen. Chen will step down effective December 31, 2021. Metacrine CEO Preston Klassen is likely to assume responsibility for the company's ongoing clinical trials and future clinical operations. MTCR&#x...

SAN DIEGO, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that Hubert C. Chen, M.D., chief medical officer, has resigned to...

Gainers: Society Pass Incorporated Common  SOPA +260%. Bluerock Residential Growth REIT BRG +71%. Can-Fite BioPharma  CANF +67%. Galera Therapeutics (NASDAQ:GRTX) +42%. AeroClean Technologies. (NASDAQ:AERC) +38%. Losers: Summit Therapeutics  SMMT -...

Gainers: Society Pass (NASDAQ:SOPA) +237%. Bluerock Residential Growth (NYSE:BRG) +71%. Can-Fite (NYSE:CANF) +59%. AeroClean (NASDAQ:AERC) +58%. Galera Therapeutics (NASDAQ:GRTX) +38%. Verso (NYSE:VRS) +35%. Roivant (NASDAQ:ROIV) +26%. Venus (NASDAQ:VERO) +25%. BioCardia (NASDAQ:BCDA) +1...

GAINERS: SK Telecom  (NYSE:SKM) +74%. Genfit  (NASDAQ:GNFT) +59%. Spruce Biosciences (NASDAQ:SPRB) +54%. Stran & Company. Warrant (NASDAQ:STRNW) +34%. Bellerophon Therapeutics (NASDAQ:BLPH) +31%. LOSERS: Pasithea Therapeutics  (NASDAQ:KTTA) -17%. Metacrine (N...

Fed Chair Jerome Powell took the podium this afternoon following a 2-day FOMC meeting. Reiterating improving labor conditions and maximum employment thanks to job gains over the last few months, markets turned green on Wednesday afternoon. At the same time, the Fed’s ramp-up of taper...

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today reported its third-quarter 2021 financial results. “Our recent...

-   Validates therapeutic benefit of combination approaches for a large segment of NASH patients -   Demonstrates additive efficacy results and favorable tolerability profile SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clin...

The race is on to get a commercial biotech treatment asset targeting Nonalcoholic steatohepatitis, or “NASH”. NASH is sadly one of the fastest growing treatable major health problems on the planet right now, and analysts believe the resulting commercial opportunity could be as b...

SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today reported interim results from a Phase 2a clinical trial evaluating the effi...